Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4462 - Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Thoracic Malignancies

Presenters

Rafael Lopez Castro

Citation

Annals of Oncology (2019) 30 (suppl_5): v747-v755. 10.1093/annonc/mdz266

Authors

R. Lopez Castro1, P. Lianes2, E. Nogueron Martnez3, P. Diz Tain4, J. Calzas5, O.J. Juan Vidal6, M. Sereno Moyano7, M.A. Muñoz8, M. Guillot Morales9, L. Capdevila Riera10, J.A. Campillo Fuentes11, J. Valdivia-Bautista12, M. Cobo Dols13, A. Paredes Lario14, X. Mielgo Rubio15, M. Majem Tarruella16, M. Martínez17, J.M. Sanchez Torres18, B. Rubio-Viqueira19, M. Provencio20

Author affiliations

  • 1 Medical Oncology, University Clinical Hospital of Valladolid, 47011 - Valladolid/ES
  • 2 Department Of Medical Oncology, Hospital de Mataro - Consorcio Sanitario del Maresme, 8304 - Mataro/ES
  • 3 Oncologia, Complejo Hospitalario Universitario de Albacete, 02006 - Albacete/ES
  • 4 Oncology, Complejo Asistencial Universitario de León, 24071 - Leon/ES
  • 5 Department Of Medical Oncology, Hospital Universitario de Fuenlabrada, 28942 - Fuenlabrada, Madrid/ES
  • 6 Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 7 Department Of Medical Oncology, Hospital Infanta Sofia, 28702 - Madrid/ES
  • 8 Department Of Medical Oncology, IVO - Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 9 Oncology, Hospital Universitario Son Espases, 07120 - Palma de Mallorca/ES
  • 10 Department Of Medical Oncology, Hospital Sant Pau i Santa Tecla, 43003 - Tarragona/ES
  • 11 Department Of Medical Oncology, Hospital Clinico Universitario Virgen de la Arrixaca, 30120 - El Palmar/ES
  • 12 Oncologia Médica, Hospital Universitario Virgen de las Nieves, 18014 - Granada/ES
  • 13 Department Of Medical Oncology, Hospital Regional Universitario de Málaga, 29009 - Málaga/ES
  • 14 Medical Oncology, Hospital Universitario Donostia, 20014 - San Sebastián/ES
  • 15 Medical Oncology, Hospital Universitario Fundación Alcorcón, 28922 - Alcorcon/ES
  • 16 Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona/ES
  • 17 Department Of Medical Oncology, Hospital Universitario de Araba, Vitoria-Gasteiz/ES
  • 18 Department Of Medical Oncology, Hospital Universitario de La Princesa, 28006 - Madrid/ES
  • 19 Medical Oncology, Hospital Universitario Quirón Madrid, 28223 - Pozuelo de Alarcon/ES
  • 20 Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 - Madrid/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4462

Background

Lung cancer is the leading cause of cancer mortality worldwide with more than 2 million new cases and 1.8 million deaths in 2018. The TTR could be of use to objectively understand the clinical reality of lung cancer in Spain.

Methods

Observational cohort multicenter study performed in Spain. Enrollment took place between Aug’16 and Dec’18. Evaluation included a review of demographic data.

Results

6600 patients in 56 Spanish hospitals were included. Median age at diagnosis was 64 in advanced disease and 65 in early-stage. The majority of patients presented with advanced, stage III (n = 1874, 28.4%) or IV (n = 3446, 52.2%) at diagnosis, independently of gender (63.1% in males; 70.6% in females). There was a higher number of patients with no comorbidities at diagnosis in advanced disease than in early-stage (63.4% vs. 36.6%, p < 0.001) Significant differences (p < 0.001, unless indicated) observed between the two groups in the prevalence of cardiopathy, dyslipidemia (p = 0.043), COPD, hypercholesterolemia (p = 0.026), hypertension, nephropathy (p = 0.012), obesity (p = 0.007) and vasculopathy. Prevalence of symptoms (cough, pain, dyspnea, hemoptysis, weight loss, anorexia, and asthenia) was higher (p < 0.001) in advanced disease. No association found between professional occupation and stage at diagnosis, but according to exposure to carcinogenic compounds. A higher % of patients with advanced disease was observed over exposed to arsenic compounds (87.5% vs. 65.1%, p = 0.02) and acrylonitrile (75.0% vs. 65.1%, p = 0.02). Early-stage disease more prevalent among patients exposed to asbestos (47.5% vs. 34.9%, p = 0.02), radon/silica (47.4% vs. 34.9%, p = 0.02) and paintings (38.1% vs. 34.9%, p = 0.02) and diesel smoke (38.2% vs. 34.9%, p = 0.02) More patients with personal history of cancer had early-stage vs advanced disease (47.6% vs. 34.9%, p < 0.001); no differences found in stage according to family history of cancer.

Conclusions

The RTT provides information on comorbidities, risk associations, personal and family history of cancer necessary for the knowledge of lung cancer in real life, which could even be useful when planning the analysis of national health policies.

Clinical trial identification

NCT02941458.

Editorial acknowledgement

Legal entity responsible for the study

Spanish Lung Cancer Group.

Funding

Novartis, MSD, Lilly.

Disclosure

M. Provencio: Advisory / Consultancy: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.